Lucero will ring in the new year with generous funding from the European Innovation Council (EIC) to continue the development of our 3D cell culture handling platform.
The funding comes at a perfect time as Lucero transitions from the lab towards the market. Key functionalities will be developed to accommodate the use of Lucero’s system in drug development workflows and the team aims to test their prototype on site by the end of the project.
We’re grateful for the continued support demonstrated by the Commission. This funding will put us in a great position to begin testing our prototype with potential customers and transition closer to the market. We’re very excited to kick the project off! – Christopher Jacklin, co-founder of Lucero
Lucero aims to enable pharmaceutical companies to take the next step towards personalised treatments by providing a novel cell-handling platform that combines microfluidics, optical tweezers, and artificial intelligence. Our technology is tailored to pre-clinical drug screening procedures for which patient-derived 3D cell cultures have to be automatically selected, isolated, and prepared for drug testing at high throughput speed, in line with our customers’ scalability requirements.
You can read more about Lucero’s Transition project here.
